Biopharmaceutical products company Sinovac Biotech Ltd (NASDAQ:SVA) announced on Friday that it recorded a net income attributable to common shareholders of USD6.3m (USD0.06 per basic and diluted share) for the third quarter ended 30 September 2019.
This reflects a decline in earnings when compared with net income attributable to common shareholders of USD8.9m ( USD0.12 per basic and diluted share) in the prior year period
Sales of USD64.3m were recorded for the third quarter of 2019, a rise of 19.3% from sales of USD53.9m in the prior year period, due to higher sales of influenza vaccines.
R&D expenses of USD5.7m were recorded in the third quarter of 2019, an increase versus R&D of USD4.7m in the prior year period, as the company continued to invest in the development of its pipeline of product candidates, including sIPV, PPV and the varicella vaccine.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development